Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-24-100587
Filing Date
2024-11-20
Accepted
2024-11-20 17:00:17
Documents
70
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT ea0219315-10q_tffpharma.htm   iXBRL 10-Q 672148
2 CERTIFICATION ea021931501ex31-1_tffpharma.htm EX-31.1 11343
3 CERTIFICATION ea021931501ex31-2_tffpharma.htm EX-31.2 11556
4 CERTIFICATION ea021931501ex32-1_tffpharma.htm EX-32.1 5708
5 GRAPHIC image_001.jpg GRAPHIC 2891
  Complete submission text file 0001213900-24-100587.txt   4338181

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE tffp-20240930.xsd EX-101.SCH 43737
7 XBRL CALCULATION FILE tffp-20240930_cal.xml EX-101.CAL 30684
8 XBRL DEFINITION FILE tffp-20240930_def.xml EX-101.DEF 211582
9 XBRL LABEL FILE tffp-20240930_lab.xml EX-101.LAB 385443
10 XBRL PRESENTATION FILE tffp-20240930_pre.xml EX-101.PRE 225401
72 EXTRACTED XBRL INSTANCE DOCUMENT ea0219315-10q_tffpharma_htm.xml XML 417771
Mailing Address 2600 VIA FORTUNA, SUITE 360 AUSTIN TX 78746
Business Address 2600 VIA FORTUNA, SUITE 360 AUSTIN TX 78746 737-802-1973
TFF Pharmaceuticals, Inc. (Filer) CIK: 0001733413 (see all company filings)

EIN.: 824344737 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39102 | Film No.: 241481141
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)